TW201613891A - Substituted prolines / piperidines as orexin receptor antagonists - Google Patents
Substituted prolines / piperidines as orexin receptor antagonistsInfo
- Publication number
- TW201613891A TW201613891A TW104104642A TW104104642A TW201613891A TW 201613891 A TW201613891 A TW 201613891A TW 104104642 A TW104104642 A TW 104104642A TW 104104642 A TW104104642 A TW 104104642A TW 201613891 A TW201613891 A TW 201613891A
- Authority
- TW
- Taiwan
- Prior art keywords
- disorder
- orexin receptor
- compounds
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/179,432 US9499517B2 (en) | 2012-02-07 | 2014-02-12 | Substituted prolines / piperidines as orexin receptor antagonists |
US201462037471P | 2014-08-14 | 2014-08-14 | |
US14/460,289 US9440982B2 (en) | 2012-02-07 | 2014-08-14 | Substituted prolines/piperidines as orexin receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201613891A true TW201613891A (en) | 2016-04-16 |
Family
ID=53800603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104104642A TW201613891A (en) | 2014-02-12 | 2015-02-11 | Substituted prolines / piperidines as orexin receptor antagonists |
Country Status (3)
Country | Link |
---|---|
TW (1) | TW201613891A (fr) |
UY (1) | UY35993A (fr) |
WO (1) | WO2015123355A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2491038B1 (fr) | 2009-10-23 | 2016-04-06 | Janssen Pharmaceutica N.V. | Octahydropyrrolo[3,4-c]pyrroles disubstitués en tant que modulateurs de récepteur d'orexine |
CA2863413A1 (fr) | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Piperidines/prolines substituees en tant qu'antagonistes du recepteur de l'orexine |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
AR101558A1 (es) | 2014-08-13 | 2016-12-28 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores del receptor de orexina |
GB201601703D0 (en) * | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
TWI710557B (zh) * | 2016-02-12 | 2020-11-21 | 美商伊歐拉斯治療學公司 | 作為食慾素受體調節劑之經鹵素取代之六氫吡啶 |
CA2960253A1 (fr) | 2016-03-10 | 2017-09-10 | Janssen Pharmaceutica Nv | Methodes de traitement de la depression au moyen d'antagonistes du recepteur orexine-2 |
AU2017242027B2 (en) * | 2016-04-01 | 2020-10-08 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
CN108239019B (zh) * | 2016-12-27 | 2021-05-04 | 浙江医药股份有限公司新昌制药厂 | 一种(2s,5s或5r)-n-叔丁氧羰基-5-羟基-2-哌啶甲酸乙酯的合成方法 |
PL3619199T3 (pl) * | 2017-05-03 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)-benzoesowego |
CN111138413B (zh) * | 2018-11-01 | 2022-11-04 | 江苏豪森药业集团有限公司 | 一种细胞周期蛋白依赖性激酶抑制剂的制备方法及其中间体 |
TW202400149A (zh) * | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003262516A1 (en) * | 2002-09-18 | 2004-04-08 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
CA2863413A1 (fr) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Piperidines/prolines substituees en tant qu'antagonistes du recepteur de l'orexine |
US9440982B2 (en) * | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
-
2015
- 2015-02-11 TW TW104104642A patent/TW201613891A/zh unknown
- 2015-02-11 WO PCT/US2015/015500 patent/WO2015123355A1/fr active Application Filing
- 2015-02-11 UY UY0001035993A patent/UY35993A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY35993A (es) | 2015-08-31 |
WO2015123355A1 (fr) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201613891A (en) | Substituted prolines / piperidines as orexin receptor antagonists | |
BR112014019426A8 (pt) | Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina | |
TN2011000171A1 (en) | Isonicotinamide orexin receptor antagonists | |
IL201790A0 (en) | Pyridyl piperidine orexin receptor antagonists | |
IN2014CN02515A (fr) | ||
WO2012009258A3 (fr) | Modulateurs des récepteurs à la galanine peptidomimétiques | |
WO2008008551A3 (fr) | Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine | |
WO2007126934A3 (fr) | Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther | |
MX2009005712A (es) | Antagonistas de receptor de orexina de diazepam sustituido. | |
PL2049529T3 (pl) | Podstawione związki diazepanowe - antagoniści receptora oreksyny | |
WO2007126935A3 (fr) | Antagonistes des récepteurs de l'orexine sous forme de composés diazépane | |
BR112013029673A2 (pt) | antagonistas do receptor cb1 | |
IN2015DN00957A (fr) | ||
WO2009149485A3 (fr) | Composés destinés au traitement des amyloïdoses | |
MX2020013099A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
ATE455776T1 (de) | Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns | |
TN2012000434A1 (en) | Biparatopic abeta binding polypeptides | |
WO2012013282A8 (fr) | Carboxamides azahétérocycliques bicycliques en tant qu'inhibiteurs de la kinase p70s6k | |
CY1118848T1 (el) | Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης | |
EA201400969A1 (ru) | Новые терапевтические подходы для лечения болезни паркинсона | |
WO2014145485A3 (fr) | Modulateurs de map kinase et utilisations de ceux-ci | |
SG179203A1 (en) | Novel arylated camphenes, processes for their preparation and uses thereof | |
MA37700B1 (fr) | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments | |
WO2015013187A8 (fr) | Composés épargnant les ppar pour le traitement de maladies métaboliques | |
MX363632B (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. |